NEW SMYRNA BEACH, Fla. and BRIGHTON, England, Oct. 13, 2015 (GLOBE NEWSWIRE) — Life Care Medical Devices Limited (OTCPink:LCMD), (“Life Care,” “LCMD” or the “Company”) a medical device company focused on the development, production and distribution of non-invasive and minimally-invasive technologies, today announced the European launch of LapCap2®, an innovative device specifically designed to advance the standard of care for laparoscopic surgery by providing safe, rapid and repeatable access for minimally invasive abdominal procedures. The Company unveiled its proprietary LapCap2 device at the European Society for Gynaecological Endoscopy (ESGE) 24th Annual Conference in Budapest, Hungary.
A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7da53b41-136f-4f77-84fa-b2eacce5781f
LapCap2® is a sterile, single use, dome-shaped device that uses negative pressure to raise the abdominal wall above critical organs and vessels. This new way of creating space in laparoscopic entry while stabilizing the abdomen intuitively reduces risk of complications, enables efficient, time saving laparoscopic entry, and provides a less traumatic method of lifting a patient’s abdominal wall.
“The ESGE conference was the ideal venue to launch our first product, LapCap2,” stated Richard J. Prati, Chief Executive Officer of Life Care. “This annual meeting included some of the world’s most prestigious endoscopy clinicians, practitioners and thought leaders, which provided us with the opportunity to showcase LapCap2 for use in Europe. This is the first step in our strategy to reshape treatment paradigms by introducing LapCap2 into the estimated $560 million global laparoscopic surgical entry market.”
“LapCap2 acts as another pair of skilled hands, freeing the surgeon to concentrate fully on Veress needle entry,” explained Camran R. Nezhat, M.D. FACOG, FACS, internationally renowned minimally invasive and robotic surgeon and father of video-assisted endoscopic surgery. “There is a critical unmet need in laparoscopic surgery for consistent, reproducible entry and rapid creation of pneumoperitoneum. LapCap2 is specifically designed to address these needs. We believe LapCap2 will provide surgeons with additional confidence and advance the standard of care in laparoscopic surgery.”
“We were extremely pleased with the positive feedback and interest in LapCap2 that we received from the attendees at ESGE,” added Robin Stephens, Chief Operating Officer of the Company. “Our initial marketing strategy is focused on reshaping the treatment paradigm for the approximately 1.5 million gynaecological laparoscopic surgeries performed each year in Europe and the United States. We believe European surgeons will begin to quickly understand the importance of LapCap2.”
The Company expects to commence its U.S. launch of LapCap2 next month at the American Association of Gynecologic Laparoscopists (AAGL) Global Congress in Las Vegas, Nevada.
About the ESGE
Since its foundation in 1994, the European Society for Gynaecological Endoscopy (ESGE) has aimed to encourage the exchange of clinical experience, scientific thought and investigation among European gynaecological endoscopists and practitioners in related techniques. The ESGE encourages research and evaluation of endoscopic and related techniques. The recommendation of standards of training in gynaecological endoscopy and related specialties and the cooperation with national and international affiliated societies are further important objectives.
LapCap2® is a proprietary device specifically designed to address a critical unmet need and advance the standard of care in laparoscopic surgery. It is a dome shaped device that utilizes a negative pressure technique to raise the abdominal wall above critical organs and vessels during Veress needle entry. This new way of creating space in laparoscopic entry while stabilizing the abdomen conveys a number of benefits including: 1) Intuitively reduces the risk at the start of the procedure; 2) Enables efficient laparoscopic entry; and 3) Less traumatic method of lifting the abdominal wall.
For LapCap2 sales inquiries and orders please contact Life Care Medical Devices Limited by email at CustomerService@lcmd.com, by phone at USA/Canada 1-800-687-1389 or UK/Europe +44-(0)800-088-5368, or visit http://www.lcmd.com/lapcap2/overview.
About Life Care Medical Devices Limited
Life Care Medical Devices Limited (LCMD), is a medical device company focused on the development, production and distribution of non-invasive and minimally-invasive technologies and products that reshape the treatment paradigm for medical procedures. The Company’s lead product, LapCap2® is an innovative, proprietary device specifically designed to advance standard of care for laparoscopic surgery by providing safe, rapid and repeatable access for minimally invasive abdominal procedures. Life Care is dedicated to improving surgery by working to ensure LapCap2 becomes the global standard for laparoscopic access. Life Care is also actively pursuing a robust growth strategy to expand its portfolio through the acquisition of synergistic products and technologies. For more information, please visit www.lcmd.com and connect with the Company on Twitter, Facebook and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements regarding our prospective performance. Forward-looking statements are based on certain assumptions and describe future plans, strategies, and expectations of our company. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations include, without limitation: the ability to receive FDA and foreign regulatory approvals for our product candidates, including the LapCap2® Laparoscopic Access Device; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including the LapCap2® Laparoscopic Access Device; our ability to produce and sell any approved products and the price we are able to realize for those products; our ability to enter into and maintain collaborations with third parties for the development and commercialization of our products, including the LapCap2® Laparoscopic Access Device; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to retain and hire necessary employees and to staff our operations appropriately; and our dependence on the success of the LapCap2® Laparoscopic Access Device. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.
The photo is also available via AP PhotoExpress.
CONTACT: Investor Relations Jenene Thomas Communications, LLC Jenene Thomas Phone: 908.938.1475 Email: firstname.lastname@example.org Media Contact Razor Sharp PR Ray Young Phone: 512.633.6855 Email: email@example.com